Who
Matthew M. Walsh
Director
Company insider
Files Form 4 as: Director, Certara; Chief Financial Officer, Organon & Co; EVP, Chief Financial Officer, Allergan; EVP & Chief Financial Officer, Catalent; Director, Multi Color; Other, Gentek.
In numbers
- Trades disclosed
- 175
- Buys
- 5
- Sells
- 7
- Bought
- $848K
- Sold
- $2.8M
- Companies
- 6
- Companies where not an officer
- 3
- First trade
- 20 Mar 2006
- Last trade
- 14 May 2026
- Last filed
- 15 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 May 2026filed 15 May 2026 | CERT CertaraSoftware | SEC FORM 4 Code M | —15,757 at $0.00 | filing |
| 14 May 2026filed 15 May 2026 | CERT Certaraoption or derivative · Software | SEC FORM 4 Code M | —15,757 at $0.00 | filing |
| 14 May 2026filed 15 May 2026 | CERT Certaraoption or derivative · Software | SEC FORM 4 Code A | —33,222 at $0.00 | filing |
| 14 May 2026filed 15 May 2026 | CERT Certaraoption or derivative · Software | SEC FORM 4 Code M | —15,757 at $0.00 | filing |
| 14 May 2026filed 15 May 2026 | CERT Certaraoption or derivative · Software | SEC FORM 4 Code A | —33,222 at $0.00 | filing |
| 14 May 2026filed 15 May 2026 | CERT CertaraSoftware | SEC FORM 4 Code M | —15,757 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | OGN Organon & CoPharmaceuticals | SEC FORM 4 Code M | —12,047 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | OGN Organon & CoPharmaceuticals | SEC FORM 4 Code F | $24K4,127 at $5.70 | filing |
| 31 Mar 2026filed 2 Apr 2026 | OGN Organon & CoPharmaceuticals | SEC FORM 4 Code M | —21,546 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | OGN Organon & Cooption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —321,368 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | OGN Organon & Cooption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —83,472 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | OGN Organon & Cooption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —12,047 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | OGN Organon & Cooption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —21,546 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | OGN Organon & CoPharmaceuticals | SEC FORM 4 Code F | $42K7,380 at $5.70 | filing |
| 31 Mar 2026filed 2 Apr 2026 | OGN Organon & Cooption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —321,368 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | OGN Organon & Cooption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —83,472 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | OGN Organon & Cooption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —12,047 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | OGN Organon & Cooption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —21,546 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | OGN Organon & CoPharmaceuticals | SEC FORM 4 Code M | —12,047 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | OGN Organon & CoPharmaceuticals | SEC FORM 4 Code F | $24K4,127 at $5.70 | filing |
News
Critical Contrast: Organon & Co. (NYSE:OGN) & Xeris Biopharma (NASDAQ:XERS)OGN · tickerreport.com · 21 Oct 2026Head-To-Head Survey: Organon & Co. (NYSE:OGN) versus Xeris Biopharma (NASDAQ:XERS)OGN · themarketsdaily.com · 19 Oct 2026
0 headlines in the last 90 days name Matthew M. Walsh; 2 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.